These findings align with prior evidence showing that GLP-1 receptor agonists contribute not only to weight reduction and improved glucose control but also to cardiovascular protection, reducing MACE by 14% and hospital admission for heart failure by 11%, as well as renal protection, reducing the composite kidney outcome by 21% (18–21). The gene discussed is GLP1R; the disease is heart failure.